Filippo Pagani
About
Filippo Pagani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Filippo Pagani has authored 27 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Filippo Pagani's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Genomics and Diagnostics (8 papers) and Genetic factors in colorectal cancer (5 papers). Filippo Pagani is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Genomics and Diagnostics (8 papers) and Genetic factors in colorectal cancer (5 papers). Filippo Pagani collaborates with scholars based in Italy, United States and South Korea. Filippo Pagani's co-authors include Filippo de Braud, Giovanni Randon, Filippo Pietrantonio, Alessandra Raimondi, Maria Di Bartolomeo, Michele Prisciandaro, Giuseppe Procopio, Roberto Ferrara, Alessandro De Toma and Elena Verzoni and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.
In The Last Decade
Filippo Pagani
27 papers receiving 282 citations
Peers
Filippo Pagani
Kanwal Pratap Singh Raghav United States
Takeshi Kawakami Japan
Mustafa Karaağaç Türkiye
Rui Kitadai Japan
Keitaro Shimozaki Japan
Lu-Jun Shen China
M. Frueh Switzerland
Yingsheng Wen China
Veronica Conca Italy
Jonathan Salmond United Kingdom
Citations per year, relative to Filippo Pagani Filippo Pagani (= 1×)
peers
Kanwal Pratap Singh Raghav
Countries citing papers authored by Filippo Pagani
Since
Specialization
Citations
This map shows the geographic impact of Filippo Pagani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo Pagani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo Pagani more than expected).
Fields of papers citing papers by Filippo Pagani
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Filippo Pagani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo Pagani. The network helps show where Filippo Pagani may publish in the future.
Co-authorship network of co-authors of Filippo Pagani
This figure shows the co-authorship network connecting the top 25 collaborators of Filippo Pagani. A scholar is included among the top collaborators of Filippo Pagani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filippo Pagani. Filippo Pagani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Prisciandaro, Michele, Maria Antista, Alessandra Raimondi, et al.. (2022). Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. Frontiers in Oncology. 12. 780716–780716.
2.
Prinzi, Natalie, Francesca Corti, Martina Torchio, et al.. (2022). Metastatic pheochromocytomas and paragangliomas: where are we?. Tumori Journal. 108(6). 526–540.
3.
Toma, Alessandro De, Giuseppe Lo Russo, Diego Signorelli, et al.. (2021). Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology. 160. 103299–103299.
4.
Randon, Giovanni, Rossana Intini, Chiara Cremolini, et al.. (2021). Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. European Journal of Cancer. 161. 90–98.
5.
Lombardi, Pasquale, Daniele Rossini, Marco Maria Germani, et al.. (2021). Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Cancer Treatment Reviews. 103. 102326–102326.
6.
Pietrantonio, Filippo, Federica Morano, Sara Lonardi, et al.. (2021). 383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC). Annals of Oncology. 32. S530–S531.
7.
Corti, Francesca, Vito Amoroso, Davide Campana, et al.. (2021). Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. Journal of Clinical Oncology. 39(15_suppl). TPS4167–TPS4167.
8.
Raimondi, Alessandra, Pierangela Sepe, Mélanie Claps, et al.. (2020). Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Tumori Journal. 106(5). 406–412.
9.
Torchio, Martina, Francesca Corti, Paolo Manca, et al.. (2020). 1182P Baseline neutrophil-lymphocyte ratio and its variations after adjuvant radiotherapy predict clinical survival outcomes in locally advanced Merkel cell carcinoma (MCC). Annals of Oncology. 31. S781–S781.
10.
Rossini, Daniele, Marco Maria Germani, Filippo Pagani, et al.. (2020). Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. Clinical Colorectal Cancer. 19(3). 191–199.e6.
11.
Pietrantonio, Filippo, Giovanni Fucà, Paolo Manca, et al.. (2020). Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. Tumori Journal. 107(4). 353–359.
12.
Pagani, Filippo, Maurizio Colecchia, Pierangela Sepe, et al.. (2019). Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. Cancer Treatment Reviews. 79. 101891–101891.
13.
Rossini, Daniele, Filippo Pagani, Antonio Pellino, et al.. (2019). Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. Annals of Oncology. 30. iv118–iv118.
14.
Randon, Giovanni, Giulia Galli, Alessandro De Toma, et al.. (2019). P1.01-135 Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology. 14(10). S416–S416.
15.
Galli, Giulia, Alessandro De Toma, Filippo Pagani, et al.. (2019). Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 137. 38–42.
16.
Procopio, Giuseppe, Raffaele Ratta, Maurizio Colecchia, et al.. (2019). A phase II study of cabozantinib as first-line treatment in metastatic collecting ducts carcinoma: The BONSAI trial.. Journal of Clinical Oncology. 37(7_suppl). 578–578.
17.
Bartolomeo, Maria Di, Federica Morano, Alessandra Raimondi, et al.. (2019). Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. The Oncologist. 25(3). e460–e468.
18.
Ongaro, Elena, Chiara Cremolini, Daniele Rossini, et al.. (2019). Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. ESMO Open. 4(2). e000496–e000496.
19.
Verzoni, Elena, Alessandra Bearz, Ugo De Giorgi, et al.. (2019). A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.. Journal of Clinical Oncology. 37(7_suppl). TPS685–TPS685.
20.
Prinzi, Natalie, Andrea Anichini, Roberta Mortarini, et al.. (2018). Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Targeted Oncology. 13(5). 567–582.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kanwal Pratap Singh Raghav Breakdown of academic impact, for papers by Takeshi Kawakami Breakdown of academic impact, for papers by Mustafa Karaağaç Breakdown of academic impact, for papers by Rui Kitadai Breakdown of academic impact, for papers by Keitaro Shimozaki Breakdown of academic impact, for papers by Lu-Jun Shen Breakdown of academic impact, for papers by M. Frueh Breakdown of academic impact, for papers by Yingsheng Wen Breakdown of academic impact, for papers by Veronica Conca Breakdown of academic impact, for papers by Jonathan Salmond